Drug Discovery World

APRIL 25, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Development 52

Development Bioassay Antibody Drug Delivery 52

Drug Discovery World

APRIL 18, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Development 52

Development Bioassay Antibody Drug Delivery 52

Drug Discovery World

APRIL 10, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Development 40

Development Bioassay Antibody Drug Delivery 40

Drug Discovery World

APRIL 4, 2024

Join DDW for this free event, ‘ Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics ’, which is supported by Revvity. Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control.

Bioassay 52

Bioassay Antibody Drug Delivery Scientist 52

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. Their capacity, which facilitates the delivery of larger mRNAs and the co-delivery of multiple RNAs, enables new therapeutic mechanisms.

Bioassay 130

Bioassay Development RNA Drugs 130

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52